BSE · ASPIRA
Aspira Pathlab & Diagnostics Limited
Historical price visualisation is temporarily undergoing corporate data-licensing maintenance. Full interactive price and chart data will return following our upcoming authorized NSE/BSE data-feed deployment. Derived metrics (valuation ratios, market-cap rank), company financials, shareholding, corporate actions, and mutual-fund holdings remain available.
Market cap rank
#2,653
of 5,004 stocks
🏆 New peak
▲ 1771W
Peak #2,653 · 01 Oct 2026
Aspira Pathlab & Diagnostics Limited is a microcap company in the Healthcare space and carries a steep earnings multiple that prices in strong future growth, is growing revenue rapidly, and has a subdued return on equity.
Market Cap
141.82 Cr
P/E Ratio
2,755.60
P/B Ratio
11.60
ROE
0.42%
ROCE
2.86%
Dividend Yield
—
52W High
—
52W Low
—
Quarterly financials
| Metric | Q1 2026-27 | Q4 2025-26 | Q3 2025-26 | Q2 2025-26 |
|---|---|---|---|---|
| Revenue | 6.17 Cr | 6.52 Cr | 5.12 Cr | 8.09 Cr |
| Net Profit | -3.77 L | -68.91 L | -1.56 Cr | 1.84 Cr |
| EPS | 0.04 | 0.67 | 1.52 | 1.78 |
| Operating Profit | 5.42 L | -58.94 L | -1.46 Cr | 1.93 Cr |
Shareholding pattern
Promoter
46.58%
Public
53.42%
PUBLIC BREAKDOWN
Individuals
40.77%
Mutual fund holdings
Mutual fund holdings data for this stock hasn't been ingested yet — check back soon.
Recent corporate actions
No corporate actions on record for this stock.
Need this data in your app?
Full price history, technical indicators, and every field above via one REST API call.